Literature DB >> 26171666

The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement.

Sean C Godar1, Laura J Mosher1, Hunter J Strathman1, Andrea M Gochi2, Cori M Jones1, Stephen C Fowler1, Marco Bortolato1,3,4.   

Abstract

BACKGROUND AND
PURPOSE: The D1CT-7 mouse is one of the best known animal models of Tourette syndrome (TS), featuring spontaneous tic-like behaviours sensitive to standard TS therapies; these characteristics ensure a high face and predictive validity of this model, yet its construct validity remains elusive. To address this issue, we studied the responses of D1CT-7 mice to two critical components of TS pathophysiology: the exacerbation of tic-like behaviours in response to stress and the presence of sensorimotor gating deficits, which are thought to reflect the perceptual alterations causing the tics. EXPERIMENTAL APPROACH: D1CT-7 and wild-type (WT) littermates were subjected to a 20 min session of spatial confinement (SC) within an inescapable, 10 cm wide cylindrical enclosure. Changes in plasma corticosterone levels, tic-like behaviours and other spontaneous responses were measured. SC-exposed mice were also tested for the prepulse inhibition (PPI) of the startle response (a sensorimotor gating index) and other TS-related behaviours, including open-field locomotion, novel object exploration and social interaction and compared with non-confined counterparts. KEY
RESULTS: SC produced a marked increase in corticosterone concentrations in both D1CT-7 and WT mice. In D1CT-7, but not WT mice, SC exacerbated tic-like and digging behaviours, and triggered PPI deficits and aggressive responses. Conversely, SC did not modify locomotor activity or novel object exploration in D1CT-7 mice. Both tic-like behaviours and PPI impairments in SC-exposed D1CT-7 mice were inhibited by standard TS therapies and D1 dopamine receptor antagonism. CONCLUSIONS AND IMPLICATIONS: These findings collectively support the translational and construct validity of D1CT-7 mice with respect to TS. LINKED ARTICLES: This article is part of a themed section on Updating Neuropathology and Neuropharmacology of Monoaminergic Systems. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v173.13/issuetoc.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2015        PMID: 26171666      PMCID: PMC4908200          DOI: 10.1111/bph.13243

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

Review 1.  Tourette syndrome, associated conditions and the complexities of treatment.

Authors:  M M Robertson
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

Review 2.  Preclinical models relevant to Tourette syndrome.

Authors:  Neal R Swerdlow; Ashley N Sutherland
Journal:  Adv Neurol       Date:  2006

3.  Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice.

Authors:  Roberto Frau; Giuliano Pillolla; Valentina Bini; Simone Tambaro; Paola Devoto; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2012-08-09       Impact factor: 4.905

4.  Differential response of cortical-limbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists.

Authors:  K M Campbell; M J McGrath; F H Burton
Journal:  Eur J Pharmacol       Date:  1999-04-29       Impact factor: 4.432

Review 5.  The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission.

Authors:  Maurizio Popoli; Zhen Yan; Bruce S McEwen; Gerard Sanacora
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

6.  Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex.

Authors:  E D Abercrombie; K A Keefe; D S DiFrischia; M J Zigmond
Journal:  J Neurochem       Date:  1989-05       Impact factor: 5.372

7.  A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.

Authors:  Donald L Gilbert; Cathy L Budman; Harvey S Singer; Roger Kurlan; Richard E Chipkin
Journal:  Clin Neuropharmacol       Date:  2014 Jan-Feb       Impact factor: 1.592

8.  Clinical phenomenology of episodic rage in children with Tourette syndrome.

Authors:  Cathy L Budman; Lori Rockmore; John Stokes; Mark Sossin
Journal:  J Psychosom Res       Date:  2003-07       Impact factor: 3.006

9.  Basal and amphetamine-induced asymmetries in striatal dopamine release and metabolism: bilateral in vivo microdialysis in normal rats.

Authors:  S D Glick; J N Carlson; J L Baird; I M Maisonneuve; A E Bullock
Journal:  Brain Res       Date:  1988-11-08       Impact factor: 3.252

10.  Stereotyped and complex motor routines expressed during cocaine self-administration: results from a 24-h binge of unlimited cocaine access in rats.

Authors:  Stephen C Fowler; Herbert E Covington; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2007-02-27       Impact factor: 4.415

View more
  14 in total

1.  Behavioral fragmentation in the D1CT-7 mouse model of Tourette's syndrome.

Authors:  Andrea Santangelo; Marco Bortolato; Laura J Mosher; Giuseppe Crescimanno; Giuseppe Di Giovanni; Emanuele Cassioli; Valdo Ricca; Maurizio Casarrubea
Journal:  CNS Neurosci Ther       Date:  2018-01-03       Impact factor: 5.243

2.  Allopregnanolone is required for prepulse inhibition deficits induced by D1 dopamine receptor activation.

Authors:  Laura J Mosher; Roberto Cadeddu; Sabrina Yen; Jeffrey L Staudinger; Francesco Traccis; Stephen C Fowler; Jamie L Maguire; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2019-06-14       Impact factor: 4.905

Review 3.  What makes you tic? Translational approaches to study the role of stress and contextual triggers in Tourette syndrome.

Authors:  Sean C Godar; Marco Bortolato
Journal:  Neurosci Biobehav Rev       Date:  2016-12-08       Impact factor: 8.989

4.  Updating neuropathology and neuropharmacology of monoaminergic systems.

Authors:  Rona R Ramsay; Philippe De Deurwaerdère; Giuseppe Di Giovanni
Journal:  Br J Pharmacol       Date:  2016-07       Impact factor: 8.739

5.  Assessment of gait and sensorimotor deficits in the D1CT-7 mouse model of Tourette syndrome.

Authors:  Stephen C Fowler; Laura J Mosher; Sean C Godar; Marco Bortolato
Journal:  J Neurosci Methods       Date:  2017-01-15       Impact factor: 2.390

6.  Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release.

Authors:  Romina Pes; Sean C Godar; Andrew T Fox; Lauren M Burgeno; Hunter J Strathman; David P Jarmolowicz; Paola Devoto; Beth Levant; Paul E Phillips; Stephen C Fowler; Marco Bortolato
Journal:  Neuropharmacology       Date:  2016-11-23       Impact factor: 5.250

Review 7.  Neuroscience and actometry: An example of the benefits of the precise measurement of behavior.

Authors:  Troy J Zarcone
Journal:  Brain Res Bull       Date:  2022-04-25       Impact factor: 3.715

Review 8.  Modeling tics in rodents: Conceptual challenges and paths forward.

Authors:  Marco Bortolato; Christopher Pittenger
Journal:  J Neurosci Methods       Date:  2017-02-22       Impact factor: 2.390

9.  Animal Models of Tourette Syndrome-From Proliferation to Standardization.

Authors:  Dorin Yael; Michal Israelashvili; Izhar Bar-Gad
Journal:  Front Neurosci       Date:  2016-03-31       Impact factor: 4.677

Review 10.  Addressing the Complexity of Tourette's Syndrome through the Use of Animal Models.

Authors:  Ester Nespoli; Francesca Rizzo; Tobias M Boeckers; Bastian Hengerer; Andrea G Ludolph
Journal:  Front Neurosci       Date:  2016-04-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.